Efficacy News and Research

RSS
Inspiration presents OBI-1 pivotal study data on hemophilia at 23rd ISTH congress

Inspiration presents OBI-1 pivotal study data on hemophilia at 23rd ISTH congress

FDA accepts peginesatide NDA for anemia associated with CKD

FDA accepts peginesatide NDA for anemia associated with CKD

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Amphetamines can control ADHD symptoms in adults

Amphetamines can control ADHD symptoms in adults

Cipher net revenue decreases to $0.7 million for Q2 2011

Cipher net revenue decreases to $0.7 million for Q2 2011

THERAPY trial to evaluate benefits of catheter-based intervention for acute ischemic stroke

THERAPY trial to evaluate benefits of catheter-based intervention for acute ischemic stroke

Swedish Orphan Biovitrum, Biogen Idec announce data of rFVIIIFc Phase 1/2a trial for hemophilia A

Swedish Orphan Biovitrum, Biogen Idec announce data of rFVIIIFc Phase 1/2a trial for hemophilia A

Advaxis submits protocol revision for ADXS-HPV CIN Phase II study

Advaxis submits protocol revision for ADXS-HPV CIN Phase II study

Promising drug for Duchenne muscular dystrophy

Promising drug for Duchenne muscular dystrophy

Enrollment commences in Lutonix LEVANT 2 drug-coated balloon IDE trial for PAD

Enrollment commences in Lutonix LEVANT 2 drug-coated balloon IDE trial for PAD

Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy

Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

Combination strategies more effective for reducing population of tiger mosquitos

Combination strategies more effective for reducing population of tiger mosquitos

PNH patients applaud pan-Canadian approach to providing equitable access to Soliris

PNH patients applaud pan-Canadian approach to providing equitable access to Soliris

Circumcision prevents HIV transmission & cocktail of anti-HIV drugs prolong life

Circumcision prevents HIV transmission & cocktail of anti-HIV drugs prolong life

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Health Canada approves SPRYCEL as first-line treatment for life-threatening blood cancer

Combination of strategies reduces more than half the number of tiger mosquitos

Combination of strategies reduces more than half the number of tiger mosquitos

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.